There is no commercial support for this activity.

About the speaker

Scott Leibowitz, MD is a child & adolescent psychiatrist, Medical Director of Behavioral Health Services for the THRIVE Gender Development Program at Nationwide Children’s Hospital in Columbus, OH, and Associate Clinical Professor of Psychiatry at the Ohio State University College of Medicine. He completed his fellowship training at Boston Children’s Hospital and Harvard Medical School, where he first began working with transgender youth at the hospital’s multidisciplinary Gender Management Service, the first clinic of its kind in the United States. He is the co-lead for the Adolescent chapter for the World Professional Association of Transgender Health’s Standard of Care 8^th version and was elected to WPATH’s Board of Directors in 2022. He is also the lead child and adolescent faculty trainer, and curriculum co-chair for the WPATH Global Education Institute, where he has led trainings both nationally and internationally including in Israel, Japan, and Vietnam. He led the Sexual Orientation Gender Identity Issues Committee for the American Academy of Child and Adolescent Psychiatry as co-chairperson from 2013-2021 and was lead author for its conversion therapy policy statement. He also served as an expert witness in 2016 for the United States Department of Justice in its legal action against the State of North Carolina for its anti-transgender HB2 bill, among other federal cases that ruled in favor of transgender youths’ rights.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

Scott Leibowitz, MD, reports that he has no relationships with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. He will not discuss any commercial products or services. He will discuss off-label uses of GnRH agonist for puberty suppression. All conflicts have been mitigated through review. 

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Todd Peters, MD, Deepak Prabhakar, MD, Elizabeth Ryznar, MD, MSc, Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PsyD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Stacey Garnett, RN, MSN, Octavia Coit, MN, Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.